{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T09:58:10Z","timestamp":1779184690122,"version":"3.51.4"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,9,2]],"date-time":"2019-09-02T00:00:00Z","timestamp":1567382400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012164","name":"National High-tech Research and Development Program","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012164","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1016\/j.biopha.2019.109430","type":"journal-article","created":{"date-parts":[[2019,9,10]],"date-time":"2019-09-10T16:29:22Z","timestamp":1568132962000},"page":"109430","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["A novel human anti-BAFF neutralizing monoclonal antibody derived from in vitro immunization"],"prefix":"10.1016","volume":"119","author":[{"given":"Yue","family":"Tong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shengwei","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhenzhen","family":"Shan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenbing","family":"Yao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong","family":"Tian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2019.109430_bib0005","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1126\/science.285.5425.260","article-title":"BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator","volume":"285","author":"Moore","year":"1999","journal-title":"Science"},{"key":"10.1016\/j.biopha.2019.109430_bib0010","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1084\/jem.189.11.1747","article-title":"BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth","volume":"189","author":"Schneider","year":"1999","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.biopha.2019.109430_bib0015","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1111\/j.1365-2567.2006.02377.x","article-title":"Role of BAFF and APRIL in human B-cell chronic lymphocytic leukaemia","volume":"118","author":"Haiat","year":"2006","journal-title":"Immunology"},{"key":"10.1016\/j.biopha.2019.109430_bib0020","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1038\/nri2572","article-title":"Cracking the BAFF code","volume":"9","author":"Mackay","year":"2009","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.biopha.2019.109430_bib0025","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1084\/jem.190.11.1697","article-title":"Mice transgenic for baff develop lymphocytic disorders along with autoimmune manifestations","volume":"190","author":"Mackay","year":"1999","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.biopha.2019.109430_bib0030","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1038\/nrrheum.2013.136","article-title":"Future prospects in biologic therapy for systemic lupus erythematosus","volume":"9","author":"Stohl","year":"2013","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.biopha.2019.109430_bib0035","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1038\/s41467-018-03620-2","article-title":"BAFF-neutralizing interaction of belimumab related to its therapeutic efficacy for treating systemic lupus erythematosus","volume":"9","author":"Shin","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.biopha.2019.109430_bib0040","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1172\/JCI0214121","article-title":"Association of BAFF\/BLyS overexpression and altered B cell differentiation with Sj\u00f6gren\u2019s syndrome","volume":"109","author":"Groom","year":"2002","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.biopha.2019.109430_bib0045","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1056\/NEJMct1207259","article-title":"Belimumab for systemic lupus erythematosus","volume":"368","author":"Hahn","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2019.109430_bib0050","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/nbt.2076","article-title":"The discovery and development of belimumab: the anti-BLyS\u2013lupus connection","volume":"30","author":"Stohl","year":"2012","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.biopha.2019.109430_bib0055","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1242\/jcs.091876","article-title":"Localization of glypican-4 in different membrane microdomains is involved in the regulation of Wnt signaling","volume":"125","author":"Sakane","year":"2012","journal-title":"J. Cell. Sci."},{"key":"10.1016\/j.biopha.2019.109430_bib0060","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1038\/nrd3229","article-title":"Development trends for human monoclonal antibody therapeutics","volume":"9","author":"Nelson","year":"2010","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.biopha.2019.109430_bib0065","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.coi.2008.06.004","article-title":"Fully human antibodies from transgenic mouse and phage display platforms","volume":"20","author":"Lonberg","year":"2008","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.biopha.2019.109430_bib0070","doi-asserted-by":"crossref","first-page":"3995","DOI":"10.1073\/pnas.85.11.3995","article-title":"Human monoclonal antibodies produced by primary in vitro immunization of peripheral blood lymphocytes","volume":"85","author":"Borrebaeck","year":"1988","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.biopha.2019.109430_bib0075","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.yexcr.2017.01.020","article-title":"Rapid de novo generation of antigen specific human B cells with expression of Blimp\u20101 and AID by in vitro immunization","volume":"352","author":"Fang","year":"2017","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.biopha.2019.109430_bib0080","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.jim.2007.12.005","article-title":"A rapid and efficient strategy to generate antigen-specific human monoclonal antibody by in vitro immunization and the phage display method","volume":"332","author":"Matsumoto","year":"2008","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.biopha.2019.109430_bib0085","doi-asserted-by":"crossref","first-page":"4337","DOI":"10.1073\/pnas.0900507106","article-title":"Mechanistic studies of the immunochemical termination of self-tolerance with unnatural amino acids","volume":"106","author":"Gr\u00fcnewald","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.biopha.2019.109430_bib0090","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1002\/art.38237","article-title":"A single functional group substitution in c5a breaks B cell and T cell tolerance and protects against experimental arthritis","volume":"66","author":"Kessel","year":"2014","journal-title":"Arthritis Rheumatol. (Hoboken, N.J.)"},{"key":"10.1016\/j.biopha.2019.109430_bib0095","doi-asserted-by":"crossref","first-page":"11276","DOI":"10.1073\/pnas.0804157105","article-title":"Immunochemical termination of self-tolerance","volume":"105","author":"Gr\u00fcnewald","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.biopha.2019.109430_bib0100","first-page":"1","article-title":"De novo generation of specific human IgGs by in vitro immunization using autologous proteins containing immunogenic p-nitrophenylalanine","author":"Tong","year":"2018","journal-title":"mAbs"},{"key":"10.1016\/j.biopha.2019.109430_bib0105","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.pep.2005.01.001","article-title":"Expression, refolding, and characterization of human soluble BAFF synthesized in Escherichia coli","volume":"41","author":"Cao","year":"2005","journal-title":"Protein Expr. Purif."},{"key":"10.1016\/j.biopha.2019.109430_bib0110","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.febslet.2006.12.060","article-title":"sBAFF mutants induce neutralizing antibodies against BAFF","volume":"581","author":"Gao","year":"2007","journal-title":"FEBS Lett."},{"key":"10.1016\/j.biopha.2019.109430_bib0115","doi-asserted-by":"crossref","first-page":"12821","DOI":"10.1073\/pnas.1110042108","article-title":"Loss of CD4 T-cell-dependent tolerance to proteins with modified amino acids","volume":"108","author":"Gauba","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.biopha.2019.109430_bib0120","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1084\/jem.20081886","article-title":"Follicular helper T cells are required for systemic autoimmunity","volume":"206","author":"Linterman","year":"2009","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.biopha.2019.109430_bib0125","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1038\/ni.3054","article-title":"Pathophysiology of T follicular helper cells in humans and mice","volume":"16","author":"Ueno","year":"2015","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.biopha.2019.109430_bib0130","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1146\/annurev-immunol-041015-055605","article-title":"Follicular helper t cells","volume":"34","author":"Vinuesa","year":"2016","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.biopha.2019.109430_bib0135","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1128\/iai.36.1.59-65.1982","article-title":"Human peripheral blood lymphocyte activation by protein A from Staphylococcus aureus","volume":"36","author":"Chen","year":"1982","journal-title":"Infect. Immun."},{"key":"10.1016\/j.biopha.2019.109430_bib0140","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1007\/s10096-010-1136-3","article-title":"Antibody responses in furunculosis patients vaccinated with autologous formalin-killed Staphylococcus aureus","volume":"30","author":"Holtfreter","year":"2011","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"10.1016\/j.biopha.2019.109430_bib0145","doi-asserted-by":"crossref","first-page":"3253","DOI":"10.1002\/art.11299","article-title":"Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator","volume":"48","author":"Baker","year":"2003","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.biopha.2019.109430_bib0150","first-page":"396","article-title":"Pharmacokinetics and immunological effects of exogenously administered recombinant human B lymphocyte stimulator (BLyS) in mice","volume":"296","author":"Parry","year":"2001","journal-title":"J. Pharmacol. Exp. Ther."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332219324011?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332219324011?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,12]],"date-time":"2024-11-12T16:06:24Z","timestamp":1731427584000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332219324011"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":30,"alternative-id":["S0753332219324011"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2019.109430","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2019,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A novel human anti-BAFF neutralizing monoclonal antibody derived from in vitro immunization","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2019.109430","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"109430"}}